Download our whitepaper,

Arrhythmia Clinical Trials:
Advanced Cardiac Monitoring

What's Inside:

  • Continuous cardiac monitoring technologies.
  • Atrial fibrillation detection and management.
  • Antiarrhythmic drug development strategies.
  • Device-based arrhythmia interventions.
  • Patient-reported symptom correlation with ECG data.
  • Long-term rhythm monitoring and follow-up.

Access your complimentary whitepaper today:






    Pulmonary Arterial Hypertension

    Pulmonary Arterial Hypertension (PAH) is a rare but life-threatening condition characterized by elevated blood pressure in the pulmonary arteries, which connect the heart to the lungs.

    The increased pressure results from the narrowing and stiffening of these arteries, leading to restricted blood flow. As a consequence, the right side of the heart has to work harder to pump blood through the lungs. Over time, this extra strain can cause right heart failure, a primary cause of death in patients with PAH. If left untreated, PAH can be fatal within a few years of diagnosis.

    iNGENū’s team of researchers and clinicians is dedicated to advancing Pulmonary Arterial Hypertension research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by Pulmonary Arterial Hypertension.

    Women are

    3x

    more likely to develop PAH

    40%

    of patients with untreated PAH develop right heart failure

    10%

    of PAH cases are heritable, often involving mutations in the BMPR2 gene

    Our clinical team has over

    120

    years of combined clinical trial experience